We are always looking to connect with other organizations that share our mission to transform the lives of patients with cancer. Our partnering strategy focuses on expanding our ability to deliver novel cancer therapies that meet the needs of patients with aggressive cancers.
We can’t wait to hear from you. If you are interested in partnering opportunities, reach out via the form below.
Ayala collaborates with companies for the betterment of patients with rare and aggressive cancers.
Our current partners
We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, in November 2017.
We are collaborating with Novartis International Pharmaceutical Limited, or Novartis, to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis’ B-cell maturation antigen, or BCMA, targeting therapies, since 2018.